News

News and Press Releases
Advocacy | Insurance | Public Policy CF Foundation Urges Vertex Pharmaceuticals to Reverse Consequential Decision on Copay Assistance

206 care center directors sign a letter citing clinical consequences if decision moves forward. 

| 3 min read
Newly Expanded Cystic Fibrosis Foundation Lab Will Enable More Research Into Genetic Therapies

The physical footprint of the Cystic Fibrosis Foundation Therapeutics Lab grew by about a third this year, enabling startup companies and industry scientists to work and learn alongside lab staff.

| 4 min read
About the CF Foundation | Antibiotics | Infection Prevention and Control CF Foundation Invests Up to $4.85 Million in Aridis Pharmaceuticals for Testing of Anti-Infective

The investment will go toward finishing a Phase 2a clinical trial for an anti-infective to treat chronic infections in people with CF.

| 2 min read
About the CF Foundation Cystic Fibrosis Foundation Announces Irena Barisic as Next Chief Operating and Financial Officer

Barisic Will Transition from Current Role as Chief Financial and Administrative Officer in January 2023

| 3 min read
Advocacy | Insurance | Public Policy CF Foundation Urges Vertex Pharmaceuticals to Address Its Decision to Decrease Copay Assistance for People with Cystic Fibrosis

Vertex’s copay assistance changes add an undue burden for people living with an already expensive, challenging lifelong disease.

| 3 min read
Advocacy | Antibiotics | Public Policy 165 Organizations Urge Lawmakers to Advance PASTEUR Act Before Congress Ends

Bill will jump-start rebuilding of the antibiotics pipeline that is vital to stave off a looming pandemic.

| 3 min read
Research Simplify Study Indicates Potential to Reduce Medication Burden for People With CF Taking Trikafta

Results show that people on Trikafta® enrolled in the six-week study were able to safely stop taking one of the two common CF medications without negatively affecting their health.

| 4 min read
About the CF Foundation | Our Research Approach CF Foundation Provides Additional Funding to Carmine Therapeutics for Early-Stage Research Into Potential Genetic Therapy

The Cystic Fibrosis Foundation is providing up to $5 million to develop a method to deliver a healthy copy of the CFTR gene into the lung cells of people with CF that is unlikely to trigger an immune system response.

| 4 min read
About the CF Foundation | Diagnosis CF Foundation Continues Working Toward Equity and Timeliness in Cystic Fibrosis Newborn Screening

Addressing variability in newborn screening can prevent missed diagnoses and delays in early care intervention.

| 3 min read
CFTR Modulators FDA Approves Orkambi for Children With CF Ages 1 to 2 Years

Orkambi® is now approved for use in children with cystic fibrosis ages 1-2 years who have two F508del mutations. This is the only modulator available to very young children with these mutations.

| 3 min read